Sung Ji Nam
Stock Analyst at Scotiabank
(3.69)
# 787
Out of 5,131 analysts
83
Total ratings
50.72%
Success rate
8.79%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Sector Outperform | $57 → $60 | $110.17 | -45.54% | 6 | Jul 31, 2025 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $90 → $75 | $65.70 | +14.16% | 3 | Jul 11, 2025 | |
| DHR Danaher | Upgrades: Sector Outperform | $275 | $238.37 | +15.37% | 2 | Jul 11, 2025 | |
| TMO Thermo Fisher Scientific | Upgrades: Sector Outperform | $590 | $618.86 | -4.66% | 15 | Jul 11, 2025 | |
| ILMN Illumina | Downgrades: Sector Perform | $125 | $141.07 | -11.39% | 10 | Jul 11, 2025 | |
| CSTL Castle Biosciences | Maintains: Sector Outperform | $44 → $40 | $39.34 | +1.68% | 6 | May 21, 2025 | |
| BDSX Biodesix | Maintains: Sector Outperform | $60 → $40 | $5.46 | +632.60% | 2 | May 21, 2025 | |
| MYGN Myriad Genetics | Downgrades: Sector Perform | $20 → $6 | $6.58 | -8.81% | 4 | May 21, 2025 | |
| BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $1.58 | +153.16% | 6 | Apr 2, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $1.94 | +3.09% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $73 | $102.11 | -28.51% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $10 → $12 | $15.78 | -23.93% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $430 → $450 | $396.75 | +13.42% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $54 → $62 | $35.32 | +75.54% | 5 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $42.04 | +4.66% | 4 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $17.13 | +104.32% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $4.19 | +43.20% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $27.85 | - | 3 | Nov 24, 2020 |
Guardant Health
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $57 → $60
Current: $110.17
Upside: -45.54%
Bio-Techne
Jul 11, 2025
Maintains: Sector Outperform
Price Target: $90 → $75
Current: $65.70
Upside: +14.16%
Danaher
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $275
Current: $238.37
Upside: +15.37%
Thermo Fisher Scientific
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $590
Current: $618.86
Upside: -4.66%
Illumina
Jul 11, 2025
Downgrades: Sector Perform
Price Target: $125
Current: $141.07
Upside: -11.39%
Castle Biosciences
May 21, 2025
Maintains: Sector Outperform
Price Target: $44 → $40
Current: $39.34
Upside: +1.68%
Biodesix
May 21, 2025
Maintains: Sector Outperform
Price Target: $60 → $40
Current: $5.46
Upside: +632.60%
Myriad Genetics
May 21, 2025
Downgrades: Sector Perform
Price Target: $20 → $6
Current: $6.58
Upside: -8.81%
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $1.58
Upside: +153.16%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $1.94
Upside: +3.09%
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $70 → $73
Current: $102.11
Upside: -28.51%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $15.78
Upside: -23.93%
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $396.75
Upside: +13.42%
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $35.32
Upside: +75.54%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $42.04
Upside: +4.66%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $17.13
Upside: +104.32%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $4.19
Upside: +43.20%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $27.85
Upside: -